Bringing the Oncology Community Together

Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer

Ben Leach
Published Online: Tuesday, June 4, 2013
G. Thomas Budd, MD

G. Thomas Budd, MD

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer, according to the results of a phase III study presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Paclitaxel is typically prescribed in either weekly or biweekly regimens. This is the first study to formally compare the two dosing schedules. The low-dose weekly administration of the chemotherapy agent paclitaxel resulted in equal disease-free survival (DFS) in patients with early-stage breast cancer when compared with biweekly administration of the drug, and although each dosing regimen resulted in a different set of side effects, the weekly dosing schedule appeared to offer a slightly more favorable side effect profile,

“It's important to give these drugs in an optimal way,” said G. Thomas Budd, MD, a medical oncologist at the Cleveland Clinic in Cleveland, Ohio, and lead author of the study. Budd noted that paclitaxel used to be given in higher doses every three weeks in the treatment of breast cancer until studies showed that the weekly and biweekly schedules in this study yielded superior results.

In this phase III trial, 3294 patients with node-positive or high-risk node-negative operable breast cancer first received treatment with one of three different regimens of doxorubicin and cyclophosphamide, after which they were randomized to receive either a low-dose regimen of paclitaxel weekly for 12 weeks or a standard-dose regimen of paclitaxel every two weeks for 12 weeks with pegfilgrastim support.

As of April 2013, DFS was essentially the same with both schedules of paclitaxel (hazard ratio [HR] = 1.05, 95% CI, 0.89–1.25).

“It appears from these data that either way of giving paclitaxel produces a similar outcome,” Budd said. “An investigator and a patient or a doctor and a patient could choose either one of these schedules.”

The rate of any grade 3-4 toxicity was similar across the two arms, occurring in 36% of patients receiving the biweekly regimen and 35% of patients receiving the weekly regimen. However, researchers found that the different dosing schedules were characterized by different types of side effects of different severities. Allergic reactions were more common in the biweekly dose (1.4%) compared with the lower dose (0.6%) as were symptoms of bone and muscle pain (11% vs 3%, respectively). Neurologic toxicity was also more frequent in the biweekly dose of paclitaxel compared with the low-dose regimen (17% vs 10%, respectively), but Budd noted that patients received six cycles of the biweekly regimen instead of the standard four cycles for the purposes of scientific comparison, which may have affected the frequency of these side effects slightly.

The rate of hematologic toxicity was higher in the weekly dose arm (17%) than the biweekly dose arm (6%), as was the rate of leukopenia (6% vs 1%, respectively) and neutrophils (11% vs 2%, respectively). However, the rate of neutropenic fever was low in both groups (0.4% vs 0.1%, respectively) and the difference was not statistically significant (P = .29). Budd explained that the higher rates of hematologic toxicity in the weekly schedule could have been a result of ascertainment bias, since patients had toxicities measured on a weekly basis rather than the biweekly basis of the other study arm.

“In this study, the weekly schedule seemed to be less toxic for most patients,” Budd said.
Budd GT, Barlow WE, Moore HCF, et al. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol. 2013;31(suppl; abstr CRA1008).

<<< View more from the 2013 ASCO Annual Meeting

Related Articles
Experts Debate Utility of Genomic Profiling in Daily Practice
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.